<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191201</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01449</org_study_id>
    <nct_id>NCT03191201</nct_id>
  </id_info>
  <brief_title>A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.</brief_title>
  <acronym>DIAFER</acronym>
  <official_title>A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof Gérard WAEBER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Policlinique Médicale Universitaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lausanne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators aim at addressing potential relationships between iron stores
      and glucose homeostasis. Iron (i.e. Ferric Carboxymaltose) will be perfused to
      pre-menopausal, iron-deficient non-anaemic women suffering from a chronic fatigue syndrome
      and parameters related to glucose homeostasis, parameters related to metabolic syndrome and
      inflammation will be measured before and after the intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">April 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 12, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind randomised placebo-controlled, parallel group comparative inferiority study with open-label extension divided in two parts:
A first randomised and double-blind part in which FCM or placebo will be administered at baseline and post-baseline parameters assessed.
A second non-randomised, non-blinded open-label extension part starting at the end of part 1, in which participants randomised to the placebo group will receive a FCM injection and post-baseline parameters assessed.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>To ensure that patients are unaware of the study drug they are receiving, the infusion pouch will be prepared in a separate room by members of the pharmacy unit and opaque bags will cover the infusion kits and infusions will be done via dark coloured infusion sets. Finally, a curtain will be used to shield the injection site from the patient's view.
To ensure that Outcomes Assessors are unaware of the study drug the patient is receiving, a seperate team of care providers will supervise the infusion of the investigation product and collect and/or manage adverse events (AEs) and serious adverse events (SAEs). The Outcome Assessor will not have access to participant related data during the randomised part of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in glucose homeostasis status, assessed by a dynamic two-step hyperglycaemic clamp investigation.</measure>
    <time_frame>at 28 days of the injection of the Investigation Product</time_frame>
    <description>two-step hyperglycaemic clamp investigation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ultrasensitive C-reactive protein (hs-CRP) levels at 14 days</measure>
    <time_frame>at 14 days of the injection of the Investigation Product</time_frame>
    <description>plasma hs-CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ultrasensitive C-reactive protein (hs-CRP) levels at 28 days</measure>
    <time_frame>at 28 days of the injection of the Investigation Product</time_frame>
    <description>plasma hs-CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in interleukin-6 (IL-6) levels at 14 days</measure>
    <time_frame>at 14 days of the injection of the Investigation Product</time_frame>
    <description>plasam IL-6 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in interleukin-6 (IL-6) levels at 28 days</measure>
    <time_frame>at 28 days of the injection of the Investigation Product</time_frame>
    <description>plasam IL-6 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in adiponectin levels at 14 days</measure>
    <time_frame>at 14 days of the injection of the Investigation Product</time_frame>
    <description>adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in adiponectin levels at 28 days</measure>
    <time_frame>at 28 days of the injection of the Investigation Product</time_frame>
    <description>adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in interleukin-1beta levels at 14 days</measure>
    <time_frame>at 14 days of the injection of the Investigation Product</time_frame>
    <description>IL-1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in interleukin-1beta levels at 28 days</measure>
    <time_frame>at 28 days of the injection of the Investigation Product</time_frame>
    <description>IL-1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure levels at 14 days</measure>
    <time_frame>at 14 days of the injection of the Investigation Product</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure levels at 28 days</measure>
    <time_frame>at 28 days of the injection of the Investigation Product</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the plasma lipid profile level at 14 days</measure>
    <time_frame>at 14 days of the injection of the Investigation Product</time_frame>
    <description>plasma total- and HDL-cholesterol and plasam triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the plasma lipid profile level at 28 days</measure>
    <time_frame>at 28 days of the injection of the Investigation Product</time_frame>
    <description>plasma total- and HDL-cholesterol and plasam triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Homeostasis Model Assessment (HOMA-2) index at 14 days</measure>
    <time_frame>at 14 days of the injection of the Investigation Product</time_frame>
    <description>Calculated Homeostasis Model Assessment (HOMA-2) index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Homeostasis Model Assessment (HOMA-2) index at 28 days</measure>
    <time_frame>at 28 days of the injection of the Investigation Product</time_frame>
    <description>Calculated Homeostasis Model Assessment (HOMA-2) index</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in the plasma metabolomic profiling as assessed by metabolomics</measure>
    <time_frame>at 14 and 28 days of the injection of the Investigation Product</time_frame>
    <description>Metabolomics</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in circulating miRNAs</measure>
    <time_frame>at 14 and 28 days of the injection of the Investigation Product</time_frame>
    <description>selected miRNA as measured by qPCR</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Iron-deficiency</condition>
  <condition>Iron Toxicity</condition>
  <condition>Glucose Metabolism Disorders (Including Diabetes Mellitus)</condition>
  <condition>Metabolic Side Effects of Drugs</condition>
  <condition>Metabolic Disorder, Glucose</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.
At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose</intervention_name>
    <description>Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.</description>
    <arm_group_label>Ferric carboxymaltose arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride solution</intervention_name>
    <description>250 mL of a commercially available sterile 0.9% sodium chloride solution.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women.

          -  Negative pregnancy test.

          -  Adequate contraception during the study period and for 1 month following study
             completion.

          -  Overt or relative iron deficiency at screening defined as follows:

        Serum ferritin &lt;50 ng/mL AND transferrin saturation &lt;20%, OR Serum ferritin &lt;30 ng/mL.

        - Serum C-reactive protein: &lt;5 mg/L if not on oral contraception, OR &lt;20 mg/L if use of
        oral contraception

          -  Intolerance to oral iron formulations, or lack of efficacy of oral iron formulations.

          -  Minimum total score of 5 on the Visual analogic scale of fatigue.

          -  Normal levels of vitamin B12 and folic acid at screening.

          -  Availability and willingness to complete all study visits and procedures per protocol.

          -  Ability to sign an informed consent.

        Exclusion Criteria:

          -  Age &lt;18 years.

          -  Menopause (defined as an amenorrhea of at least 12 months).

          -  Irregularly menstruating women (menstrual cycle outside a range of 24-38 days in
             duration) or experiencing overt metrorrhagia (simple spotting not being an exclusion
             criteria).

          -  Body mass index &lt;18.5 kg/m2 or &gt;30 kg/m2.

          -  Diabetes, defined as subjects with HbA1c ≥ 6.5 % and/or with fasting blood glucose
             levels ≥ 7 mmol/l and/or with a history of diabetes and/or by the use of anti-diabetic
             drugs.

          -  Hb level &lt;117 g/L or known haemoglobinopathy or haemochromatosis.

          -  Blood transfusion within the last 12 weeks.

          -  Intake of iron preparations 4 weeks prior to screening.

          -  Known hypersensitivity to FCM or to any other iron preparation.

          -  Suspicion of major depressive disorder based on Patient Health Questionnaire.

          -  Known chronic inflammatory disease, including human immunodeficiency virus, hepatitis
             B or hepatitis C virus infection.

          -  Active malignancy.

          -  Decreased renal function (estimated glomerular filtration rate using the CKD-EPI
             equation&lt;60 ml/min/1.73m2).

          -  Liver dysfunction (aspartate aminotransferase and alanine aminotransferase &gt; 3-fold
             upper limit).

          -  Angina (Class IV).

          -  Asthma.

          -  Documented sleep apnoea.

          -  Important recent weight loss (&gt;10% within the past month).

          -  Thyroid dysfunction (thyroid stimulating hormone &gt;4 µU/mL).

          -  Reported weekly alcohol consumption &gt; 14 standard drinks.

          -  Drug abuse (any drug consumption reported in the past 12 months).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gérard Waeber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gérard Waeber, MD</last_name>
    <phone>21 314 09 63</phone>
    <phone_ext>+41</phone_ext>
    <email>Gerard.Waeber@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evrim Jaccard, MD-PhD</last_name>
    <phone>21 556 48 79</phone>
    <phone_ext>+41</phone_ext>
    <email>Evrim.Jaccard@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinique Médicale Universitaire</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Favrat, MD</last_name>
      <phone>21 314 49 06</phone>
      <phone_ext>+41</phone_ext>
      <email>Bernard.Favrat@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Cornuz Jacques, MD</last_name>
      <phone>21 314 05 06</phone>
      <phone_ext>+41</phone_ext>
      <email>Jacques.Cornuz@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Luc Tappy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Favrat Bernard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evrim Jaccard, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérard Waeber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro-Manuel Marques-Vidal, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Froissart, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cédric Gubelmann, Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laila Baratali, Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kévin Seyssel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne</investigator_affiliation>
    <investigator_full_name>Prof Gérard WAEBER</investigator_full_name>
    <investigator_title>Head of the Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Metabolomics, Transcriptomics, Ironomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
    <mesh_term>Metabolic Side Effects of Drugs and Substances</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

